Liping Zhi

Liping Zhi


Research Focus & Metrics

Academic Career Length

4Years (2023-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
26 September 2023 in Bioorganic Chemistry
Verified
Journal Article
Closed access
QLQi Lv
Qi Lv
FZFeilong Zhou
Feilong Zhou
XLXinhua Liu
Xinhua Liu
LZLiping Zhi
Liping Zhi

18 January 2025 in RSC Medicinal Chemistry
Verified
Journal Article
Closed access
PDF file
YJYu Jie Jian
Yu Jie Jian
QLQi Lv
Qi Lv
LDLeran Du
Leran Du
CLCen Cen Lei
Cen Cen Lei
LZLiping Zhi
Liping Zhi
XLXinhua Liu
Xinhua Liu
Acute lung injury (ALI) is a multifactorial respiratory disease characterized by uncontrolled inflammatory response and has high morbidity and mortality. There is currently a lack of effective drugs for ALI treatment. In this study, through nitric oxide (NO) release inhibition and cytotoxicity screening from the in-house compound library, hit compound 6 was discovered. Using 2,4,5-trichloropyrimidine as raw material, 27 new molecules were rapidly synthesized as modified products of compound 6 through nucleophilic substitution reaction and Buchwald–Hartwig reaction. Further activity evaluation and structure–activity relationship study confirmed that compound 32 was a low-toxicity, highly efficient lead compound. Action mechanism studies indicated that compound 32 can significantly reduce the inflammatory response induced by lipopolysaccharide (LPS) in RAW264.7 cells, manifested by the down-regulation of the levels of cytokines, reactive oxygen species (ROS), and the protein expression of Toll-like receptor 4/nuclear factor-κB (TLR4/NF-κB) and Kelch-like ECH-associated protein-1/nuclear factor-erythroid 2-related factor 2/heme oxygenase-1 (Keap1-NRF2-HO-1). An in vivo anti-inflammatory study showed that it can reduce the severity of lung injury in the ALI model, accompanied by a reduction in the levels of inflammatory factors and related protein expression levels.

17 July 2024 in RSC Medicinal Chemistry
Verified
Journal Article
Closed access
PDF file
YWYumeng Wang
Yumeng Wang
CLCencen Lei
Cencen Lei
QWQuan Wang
Quan Wang
XZXingxing Zhang
Xingxing Zhang
LZLiping Zhi
Liping Zhi
XLXinhua Liu
Xinhua Liu
It is of great significance to design and synthesize novel structural inhibitors with good antitumor activity. In this study, based on rational design, a total of 42 7-azaindole derivatives as novel CDK8 inhibitors were designed and synthesized. All compounds were screened with antitumor activity and compound 6 (1-(3-((1H-pyrrolo[2,3-b]pyridin-5-yl)oxy)phenyl)-3-(m-tolyl)urea) exhibited the best activity, especially in acute myeloid leukemia (GI50 MV4-11 = 1.97 ± 1.24 μM). This compound also exhibited excellent inhibitory activity against CDK8 (IC50 = 51.3 ± 4.6 nM). Further mechanism studies shown that it could inhibit STAT5 phosphorylation and induce cell cycle arrest in the G1 phase, leading to apoptosis in acute myeloid leukemia cells. In addition, acute toxicity at a dose of 1000 mg kg−1 indicated the low toxicity of this compound.

10 June 2026 in RSC Medicinal Chemistry
Verified
Journal Article
Closed access
PDF file
XZXingxing Zhang
Xingxing Zhang
QCQingsong Chen
Qingsong Chen
CLCencen Lei
Cencen Lei
DJDa Long Jin
Da Long Jin
HLHao Dong Liu
Hao Dong Liu
XLXinhua Liu
Xinhua Liu
CDK8 exerts important physiological functions, particularly in CRC, by forming intermediate complexes with Cyclic C, MED12, and MED13. In this work, different from the design of traditional single CDK8 protac degraders, a novel potent dual target CDK8 and Cyclic C protac degrader (compound 3) were designed and synthesized. It exhibited the good degradation efficiency against CDK8 ((DC 50 =2.58 μM) and Cyclic C (DC 50 =5.48 μM), along with high selectivity that had no effect on CDK1-7 and CDK9. Importantly, compound 3 could also lower the expression of Cyclin C by reducing mRNA levels, thus better reducing the content of Cyclin C and inhibiting the formation of intermediate complex composed of CDK8, Cyclin C, MED12, and MED13 so that it could better inhibit the biological function of CDK8.Mechanism studies have shown that it had a stronger inhibitory effect on the Wnt/β -catenin signaling pathway and cell cycle regulation than compound C29. This study provides new ideas for the design of CDK8 degrading agents .